Evaluation of PD-L1 Expression in Undifferentiated Pleomorphic Sarcomas, Liposarcomas and Chondrosarcomas

Zhang, Yifan; Chen, Yi; Papakonstantinou, Andri; Tsagozis, Panagiotis; Linder-Stragliotto, Christina; Haglund, Felix

doi:10.3390/biom12020292

Cited by 7 publications

(9 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The presence of tumor-infiltrating lymphocytes and PD-L1 expression are both generally promoted by anti PD-1/L1 blockade [ 10 ]. However, Zhang et al found no significant difference in metastasis-free or overall survival in cases of liposarcoma, regardless of PD-L1 expression [ 11 ]. The effectiveness of immune checkpoint blockade therapy has recently been investigated in an open-label phase II study of anti-PD-1 monotherapy in patients with histological evidence of metastatic or surgically unresectable locally advanced sarcoma.…”

Section: Discussionmentioning

confidence: 99%

Dedifferentiated liposarcoma primary to the chest wall with spontaneous shrinking: report of a case

et al. 2023

View full text Add to dashboard Cite

An 80-year-old man presented to our emergency department complaining of a mass on the right side of his chest and pain in the right flank of his back. A chest computed tomography (CT) scan showed a relatively heterogenous oval-shaped tumor measuring 7.5 × 6.0 cm eroded to the 8th rib, with slightly dense fluid accumulation inside and calcification of the tumor wall. A 1-month follow-up CT scan showed spontaneous shrinkage of the tumor. The tumor was completely excised from the thoracic wall and the wall was reconstructed with a polytetrafluoroethylene mesh. Pathological examination showed coagulation necrosis in the chest wall tumor, but immunohistochemical staining revealed murine double minute 2- and Cyclin-dependent kinase 4-positive cells with irregular nuclear size and bizarre morphology. Therefore, dedifferentiated liposarcoma (DDLPS) was the final pathological diagnosis. Remarkable infiltration of CD8+ lymphocytes into the tumor was observed, along with a 90% positive ratio for programmed cell death-ligand 1. The patient has been followed-up for 1 year without any recurrence, despite not receiving any additional treatment. Liposarcoma is one of the most common types of soft tissue sarcomas; however, spontaneous regression of primary DDLPS arising from the chest wall is extremely rare. Herein, we report a case of DDLPS primary to the chest wall with spontaneous regression, probably due to a spontaneously induced T cell response.

show abstract

Section: Discussionmentioning

confidence: 99%

Dedifferentiated liposarcoma primary to the chest wall with spontaneous shrinking: report of a case

et al. 2023

View full text Add to dashboard Cite

show abstract

“…STS is generally described as having low PD-L1 expression with response rates range 5%-18% (11,38). Sarcomas with PD-L1 expression include angiosarcoma, chondrosarcoma, Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and UPS, among which high PD-L1 expression tends to be more common in UPS (8,34). Zhang et al (8), used the SP263 assay to measure PD-L1 expression in chondrosarcoma, liposarcoma, and UPS, respectively, and observed increased response rates in the UPS group, with TPS >50% observed in 8 tumors (8/96).…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…Zhang et al. ( 8 ), used the SP263 assay to measure PD-L1 expression in chondrosarcoma, liposarcoma, and UPS, respectively, and observed increased response rates in the UPS group, with TPS >50% observed in 8 tumors (8/96). To our knowledge, there are very few reports of PD-1 inhibitors for UPS PD-L1 high expression.…”

Section: Discussionmentioning

confidence: 99%

“…In recent years, targeted therapies using immune checkpoint inhibitors (ICIs) to block the binding between programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) achieved good responses in various malignancies such as lung cancer ( 6 ) and melanoma ( 7 ). Monoclonal antibodies against PD-1 and PD-L1 can activate T lymphocytes by blocking the PD-1/PD-L1 signaling pathway, thereby preventing tumors from achieving immune evasion ( 8 ). Treatment response is often associated with the presence of tumor-infiltrating lymphocytes (TILs) and PD-L1 expression in tumor and immune cells ( 9 ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Tislelizumab immunotherapy combined with chemotherapy in the treatment of a patient with primary anterior mediastinal undifferentiated pleomorphic sarcoma with high PD-L1 expression: A case report and literature review

Yang

Qin

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Undifferentiated pleomorphic sarcoma (UPS) is a rare and aggressive soft tissue tumor with a high degree of malignancy and rapid progression, usually occurring in the extremities, retroperitoneum, and abdomen, whereas it rarely arises in the mediastinum, and is treated mainly by surgical resection. The prognosis of patients with advanced sarcoma is poor, and doxorubicin monotherapy is the standard first-line chemotherapy for most advanced soft tissue sarcomas (STS), but the prognosis is generally unsatisfactory. Immune checkpoint inhibitors (ICIs) have been established as therapies for many solid cancers in recent years; however, evidence on the efficacy of ICIs in undifferentiated sarcoma is scarce, mostly consisting of small studies, and no ICIs are currently approved for use in sarcomas. We report a case of a middle-aged man with primary mediastinal UPS with high PD-L1 expression (TPS was approximately 80%) and TLS positive. The patient was treated with sequential tislelizumab monotherapy maintenance after 6 cycles of tislelizumab combined with epirubicin, efficacy evaluation was partial remission (PR), progression-free survival (PFS) was 8.5 months, and grade 1 fatigue was identified as an adverse event.

show abstract

Role of immunotherapy in chondrosarcoma: A case report and review of the literature

Cohen-Nowak,

Dressler,

Rock

et al. 2023

Ther Adv Med Oncol

View full text Add to dashboard Cite

Chondrosarcomas (CSs) consist of a heterogenous group of primary bone cancers arising from malignant cells which produce cartilaginous matrix. As the second most common primary bone cancer, CS are often resistant to systemic chemotherapy due to poor vascularization, slow proliferation, and expression of multidrug-resistant pumps. Immune checkpoint inhibitors have transformed the field of oncology and are now designated as frontline therapy for many solid tumor cancers. Several studies have demonstrated increased expression of programed cell death 1 (PD-1) and PD-L1 in CS tissue in vitro, which has led to the development of multiple clinical trials for immunotherapy in patients with aggressive CS. In this review, we highlight the ongoing investigation into the role for immunotherapy in CS. We also report the case of a 44-year-old female with a history of stage IV primary CS of the right shoulder who underwent radical resection with recurrence and demonstrated a spectacular sustained response to pembrolizumab at our center. Our review highlights the need for further studies investigating the role of immunotherapy in the treatment of aggressive bone sarcomas that are resistant to standard surgical resection, chemotherapy, and radiation treatment.

show abstract

Evaluation of PD-L1 Expression in Undifferentiated Pleomorphic Sarcomas, Liposarcomas and Chondrosarcomas

Cited by 7 publications

References 36 publications

Dedifferentiated liposarcoma primary to the chest wall with spontaneous shrinking: report of a case

Dedifferentiated liposarcoma primary to the chest wall with spontaneous shrinking: report of a case

Tislelizumab immunotherapy combined with chemotherapy in the treatment of a patient with primary anterior mediastinal undifferentiated pleomorphic sarcoma with high PD-L1 expression: A case report and literature review

Role of immunotherapy in chondrosarcoma: A case report and review of the literature

Contact Info

Product

Resources

About